The CEO of Actavis generic pharmaceuticals, Robert Wessman, is scheduled to speak at the annual UBS Global Specialty and Generic Pharmaceuticals Conference held in London on Wednesday 28th May.
His presentation is entitled “The strategy and competitiveness of Actavis in a fiercely competitive environment”.
The conference, held in the UK for the first time in its twelve year history, features presentations from over 80 executives of leading specialty and generic pharmaceutical companies from around the world, as well as panel discussions focused on key sector trends and issues.
Actavis is an Iceland-based generic pharmaceuticals company which specialises in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries and over 11,000 employees.
For more information on Actavis and generic pharmaceuticals visit www.actavis.com